Trial Profile
Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Aug 2012
Price :
$35
*
At a glance
- Drugs Cilengitide (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Jul 2012 Results published in Investigational New Drugs.
- 05 Nov 2010 New trial record.